AtriCure today announced the first use of its newest AtriClip device for minimally invasive concomitant procedures. Doctors used the AtriClip PRO-Mini left atrial appendage (LAA) exclusion system following its FDA 510(k) clearance earlier this year. The company built its newest device on the existing AtriClip platform, preloaded with what the company says is the smallest […]
atricure
AtriCure plans a surgical pulsed field ablation play
AtriCure (Nasdaq:ATRC) stock is up more than 16% today on news of plans to expand into pulsed field ablation, which has generated buzz as a potentially better AFib treatment. The Mason, Ohio–based company has carved out a strong niche in the surgical space. It’s technology portfolio includes the Isolator Synergy ablation clamp for treating AFib […]
AtriCure launches new CryoSphere Max cryoablation probe
AtriCure announced today that it launched the CryoSphere Max cryoablation probe. The launch comes about six months after the company launched its new CryoSphere+ cryoablation probe for the CryoIce platform. CryoSphere Max features a larger ball tip designed to optimize Cryo Nerve Block therapy (CryoNB). The new probe reduces freeze times by 50% when compared […]
AtriCure wins CE mark for EnCompass clamp device
AtriCure announced that it received CE mark for the EnCompass clamp for cardiac tissue ablation procedures. Following CE mark approval, the company says European surgeons already performed the first series of cases with EnCompass. The system received FDA 510(k) clearance and launched in the U.S. in 2022. Mason, Ohio-based AtriCure designed EnCompass for the ablation […]
AtriCure touts first case with new FDA-cleared AtriClip Flex-Mini
AtriCure today announced the first patient treated with its AtriClip Flex-Mini device. The AtriClip Flex-Mini device recently received FDA 510(k) clearance. Mason, Ohio-based AtriCure says it’s the smallest-profile left atrial appendage (LAA) device on the market. It builds upon the company’s AtriClip platform with ease of use and design simplicity for enhanced access and increased […]
AtriCure wins expanded CE mark for left atrial appendage device
AtriCure announced today that it received an expanded indication for its AtriClip devices in Europe. The expanded indication covers patients at high risk of thromboembolism for whom left atrial appendage exclusion is warranted. Mason, Ohio-based AtriCure designed its AtriClip device to exclude and electrically isolate the LAA during cardiac surgery. LAA can cause blood clots […]
AtriCure wins nod to sell AtriClip in China
AtriCure announced today that its AtriClip system received approval from regulatory authorities in China. The National Medical Products Administration (NMPA) of China approved several models of the left atrial appendage (LAA) exclusion system. AtriCure designed the device to exclude and electrically isolate the LAA during cardiac surgery. LAA can cause blood clots in patients with […]
AtriCure launches new cryoablation probe
AtriCure announced today that it launched its new CryoSphere+ cryoablation probe for the CryoIce platform. CryoSphere+ leverages new insulation technology, reducing freeze times by 25% compared to the legacy CryoSphere device. The original CryoIce device first received FDA clearance in November 2018 and aided in more than 60,000 procedures to date. The CryoSphere+ device picked […]
AtriCure grows sales by 21% in Q4
AtriCure shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast. Shares of ATRC fell 2.8% at $33.25 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.7%. The Mason, Ohio-based company posted losses of $9.8 million. That […]
AtriCure management expects Street-beating Q4 sales
AtriCure today announced preliminary fourth-quarter revenue results that beat the expectations of Wall Street analysts. The Mason, Ohio–based developer of surgical tools for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management expects to report Q4 2023 revenue of $106.5 million, up 21% year-over-year. The consensus on The Street was $102.43 million. […]
AtriCure adds J&J veteran to its board
AtriCure (Nasdaq:ATRC) announced today that it appointed longtime Johnson & Johnson executive Shlomi Nachman to its board of directors. Nachman most recently served as company group chair within the Johnson & Johnson Medical Devices (now MedTech) business. He also joined the board of transcatheter aortic valve replacement technology developer JenaValve in September. “I am thrilled […]
